drugset / Trial / NCT01302340

Delta-THC in Behavioral Disturbances in Dementia

NCT01302340

RandomizedCrossoverQuadruple-blindTreatment

Summary

Dementia is a common chronic condition, with predicted increasing prevalence. Nearly all patients with dementia will experience neuropsychiatric symptoms (NPS). This causes significant burden for the individual patients and their caregivers. Current treatment has only modest efficacy and important side-effects. Formulations with Δ9-tetrahydrocannabinol (THC), the psycho-active compound of cannabis, are currently being registered for spasms in multiple sclerosis and other diseases, and may have beneficial effects on NPS.

Timeline

Start
2011-09
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dronabinol Other / unclassified 0.75 mg Oral
Comparator Dronabinol Other / unclassified 1.5 mg Oral

Indications